Mishin Vasiliy P, Nedyalkova Marina S, Hayden Frederick G, Gubareva Larisa V
Division of Infectious Diseases and International Health, Department of Internal Medicine, Health Sciences Center, University of Virginia, 1300 Jefferson Park Avenue, P.O. Box 800473, Charlottesville, Virginia 22908, USA.
Vaccine. 2005 Apr 22;23(22):2922-7. doi: 10.1016/j.vaccine.2004.11.058.
Protective efficacy of the intranasal immunization with the neuraminidase (NA)-deficient mutant of the influenza A virus was investigated in ferrets. Despite the highly attenuated replication in vivo, the mutant completely protected the animals against the wild type virus challenge. When challenge was done with antigenic drift variants, significant reductions in the viral titers, inflammatory cell counts, and protein concentrations were observed in the nasal washes of the immunized animals. The genetically engineered NA-deficient mutant also protected animals against the challenge and induced humoral immune response against the foreign protein that replaced the NA. We conclude that the NA as antigen is dispensable in the live attenuated influenza virus vaccine and that the NA-lacking mutant can be used as a virus vector.
在雪貂中研究了用甲型流感病毒神经氨酸酶(NA)缺陷型突变体进行鼻内免疫的保护效果。尽管该突变体在体内的复制高度减毒,但它能完全保护动物免受野生型病毒的攻击。当用抗原漂移变体进行攻击时,在免疫动物的鼻洗液中观察到病毒滴度、炎性细胞计数和蛋白质浓度显著降低。这种基因工程改造的NA缺陷型突变体也能保护动物免受攻击,并诱导针对取代NA的外源蛋白的体液免疫反应。我们得出结论,在减毒活流感病毒疫苗中,NA作为抗原是可有可无的,并且缺乏NA的突变体可作为病毒载体。